+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma

Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma

Journal of Drug Targeting 16(6): 479-485

The aim of the present study was to develop a polymeric delivery system for water-insoluble drug oridonin. Amphiphilic block copolymers, poly(epsilon-caprolactone)-poly(ethylene glycol)-poly (epsilon-caprolactone) (PCL-PEO-PCL), were synthesized by ring-opening polymerization of caprolactone initiated by the hydroxyl groups of poly(ethylene glycol)6000 (PEG-6000) with stannous octoate as catalyzer. Oridonin-loaded PCL-PEO-PCL copolymer nanoparticles (ORI-PCL-PEO-PCL-NPs) were prepared by the interfacial deposition method. The mean particle size of the drug-loaded nanoparticles was 97.5 nm and the zeta potential was - 25 mV. The entrapment efficiency and actual drug loading of the nanoparticles were 87.52% +/- 1.86% and 8.63% +/- 0.49%, respectively. The antitumor activity of ORI-PCL-PEO-PCL-NPs was evaluated by measuring changes in tumor volumes, tumor weights, and survival rates of mice with grafted hepatoma (H22). The results indicated that ORI-PCL-PEO-PCL-NPs prolonged the survival time of mice and exhibited higher therapeutic efficacy compared with free oridonin. Thus, ORI-PCL-PEO-PCL-NPs may be used as a promising delivery system for liver cancer treatment.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 032664742

Download citation: RISBibTeXText

PMID: 18604660

DOI: 10.1080/10611860802200938

Related references

Oridonin-loaded poly(-caprolactone)poly(ethylene oxide)poly(-caprolactone) copolymer nanoparticles: Preparation, characterization, and antitumor activity on mice with transplanted hepatoma. Journal of Drug Targeting 16(6): 479-485, 2008

Preparation and characterization of oridonin-loaded poly ( caprolactone)-poly ( ethylene oxide)-poly (caprolactone) copolymer nanoparticles. Chinese Journal of Natural Medicines 3(5): 291-293, 2005

Preparation and characterization of self-assembled nanoparticles formed by poly(ethylene oxide)-block-poly(epsilon-caprolactone) copolymers with long poly(epsilon-caprolactone) blocks in aqueous solutions. Langmuir 23(6): 3395-3400, 2007

Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. Journal of Physical Chemistry. B 113(39): 12928-12933, 2009

Self-assembled honokiol-loaded micelles based on poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymer. International Journal of Pharmaceutics 369(1-2): 170-175, 2009

Preparation and characterization of poly(vinyl alcohol)/poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone)/nano-hydroxyapatite composite membranes for tissue engineering. Journal of Nanoscience and Nanotechnology 11(3): 2354-2360, 2011

Preparation of anionic poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymeric nanoparticles as basic protein antigen carrier. Growth Factors 25(3): 202-208, 2007

One-step preparation of poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) nanoparticles for plasmid DNA delivery. Journal of Biomedical Materials Research. Part a 86(4): 979-986, 2008

Acute toxicity evaluation of in situ gel-forming controlled drug delivery system based on biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymer. Biomedical Materials 4(2): 025002, 2009

Preparation and characterization of magnetic poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) microspheres. Journal of Materials Science. Materials in Medicine 19(3): 1033-1041, 2008

Clonazepam release from core-shell type nanoparticles of poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) triblock copolymers. International Journal of Pharmaceutics 200(2): 231-242, 2000

Preparation of magnetic microspheres based on poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymers by modified solvent diffusion method. Journal of Biomedical Nanotechnology 6(3): 287-292, 2010

Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. Journal of Controlled Release 142(3): 438-446, 2010

Biodegradability and biocompatibility of a pH- and thermo-sensitive hydrogel formed from a sulfonamide-modified poly(epsilon-caprolactone-co-lactide)-poly(ethylene glycol)-poly(epsilon-caprolactone-co-lactide) block copolymer. Biomaterials 27(30): 5178-5185, 2006

Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. International Journal of Pharmaceutics 375(1-2): 170-176, 2009